Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about GSK plc
GSK plc News
Feb 10, 2025 - accessnewswire.com
Investors Who Lost Money on GSK plc (GSK) Should Contact Levi & Korsinsky About Pending Class Action - GSK
Feb 10, 2025 - globenewswire.com
April 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against GSK
Feb 10, 2025 - globenewswire.com
ROSEN, A LEADING LAW FIRM, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – GSK
Feb 10, 2025 - businesswire.com
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages GSK plc. (GSK) Investors To Inquire About Securities Fraud Class Action
GSK plc Quantitative Score

About GSK plc
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
GSK plc Earnings & Revenue
GSK plc Financials
Table Compare
Compare GSK metrics with: | |||
---|---|---|---|
Earnings & Growth | GSK | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GSK | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GSK | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GSK | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
GSK plc Income
GSK plc Balance Sheet
GSK plc Cash Flow
GSK plc Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Buy |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
GSK plc Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 1.5441 |
Payment Date | Dividend | Frequency |
---|---|---|
2025-04-10 | 0.39315 | Quarterly |
2025-01-09 | 0.38905 | Quarterly |
2024-10-10 | 0.38567 | Quarterly |
2024-07-11 | 0.37619 | Quarterly |
2024-04-11 | 0.40606 | Quarterly |
GSK plc Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
GSK plc Executives
Name | Role |
---|---|
Ms. Emma Natasha Walmsley | Chief Executive Officer & Director |
Ms. Julie Belita Brown A.C.A. | Chief Financial Officer & Executive Director |
Mr. James Ford | Senior Vice President & Group General Counsel of Legal & Compliance |
Ms. Diana Conrad | Chief People Officer |
Mr. Tony Wood | Chief Scientific Officer and Head of R&D |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Ms. Emma Natasha Walmsley | Chief Executive Officer & Director | Female | 1969 | 6.68M |
Ms. Julie Belita Brown A.C.A. | Chief Financial Officer & Executive Director | Female | 1962 | 6.38M |
Mr. James Ford | Senior Vice President & Group General Counsel of Legal & Compliance | Male | -- | |
Ms. Diana Conrad | Chief People Officer | Female | -- | |
Mr. Tony Wood | Chief Scientific Officer and Head of R&D | Male | -- |